Anna Ljung holds a master’s degree in Economic and Business Administration from the Stockholm School of Economics. Anna Ljung has more than 15 years of experience in the pharmaceutical industry. She is currently CEO of Moberg Pharma AB, chairman of the board of directors of OncoZenge AB and member of the board of directors of Saniona AB. Previously, Anna Ljung has been CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB.
Independent of the company and the management, as well as major shareholders.
Shareholding, private and/or through companies: 0 A-shares and 0 B-shares.
Call options issued by major shareholder: 0 call options.